HK1085920A1 - Use of dihydroimidazolones for the manufacture of a medicament for the treatment of epilepsy in dogs - Google Patents

Use of dihydroimidazolones for the manufacture of a medicament for the treatment of epilepsy in dogs

Info

Publication number
HK1085920A1
HK1085920A1 HK06105907.5A HK06105907A HK1085920A1 HK 1085920 A1 HK1085920 A1 HK 1085920A1 HK 06105907 A HK06105907 A HK 06105907A HK 1085920 A1 HK1085920 A1 HK 1085920A1
Authority
HK
Hong Kong
Prior art keywords
dihydroimidazolones
epilepsy
dogs
medicament
manufacture
Prior art date
Application number
HK06105907.5A
Other languages
English (en)
Inventor
Chris Rundfeldt
Rita Dost
Wolfgang Loescher
Andrea Tipold
Klaus Unverferth
Hans-Joachim Lankau
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of HK1085920A1 publication Critical patent/HK1085920A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
HK06105907.5A 2002-10-10 2006-05-23 Use of dihydroimidazolones for the manufacture of a medicament for the treatment of epilepsy in dogs HK1085920A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41759002P 2002-10-10 2002-10-10
PCT/EP2003/011212 WO2004032938A1 (en) 2002-10-10 2003-10-09 Use of dihydroimidazolones for the treatment of epilepsy in dogs

Publications (1)

Publication Number Publication Date
HK1085920A1 true HK1085920A1 (en) 2006-09-08

Family

ID=32094042

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06105907.5A HK1085920A1 (en) 2002-10-10 2006-05-23 Use of dihydroimidazolones for the manufacture of a medicament for the treatment of epilepsy in dogs

Country Status (28)

Country Link
US (5) US20050070537A1 (nl)
EP (3) EP1553952B1 (nl)
JP (4) JP4694202B2 (nl)
KR (2) KR101110587B1 (nl)
CN (2) CN101890019A (nl)
AR (1) AR041573A1 (nl)
AT (1) ATE418337T1 (nl)
AU (2) AU2003273978B2 (nl)
BE (1) BE2013C046I2 (nl)
BR (1) BR0315225A (nl)
CA (2) CA2501772C (nl)
CY (3) CY1109961T1 (nl)
DE (1) DE60325496D1 (nl)
DK (2) DK1553952T3 (nl)
ES (2) ES2316808T3 (nl)
FR (2) FR13C0044I2 (nl)
HK (1) HK1085920A1 (nl)
HR (3) HRP20090667B1 (nl)
HU (2) HUS1300035I1 (nl)
LU (1) LU92238I2 (nl)
MX (1) MXPA05003663A (nl)
NZ (1) NZ539864A (nl)
PL (2) PL214702B1 (nl)
PT (2) PT1553952E (nl)
SI (2) SI1553952T1 (nl)
TW (2) TWI324067B (nl)
WO (1) WO2004032938A1 (nl)
ZA (1) ZA200502245B (nl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
AU2004255414A1 (en) * 2003-07-11 2005-01-20 Boehringer Ingelheim Vetmedica Gmbh Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
KR20140057604A (ko) 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
JP6193613B2 (ja) * 2013-05-10 2017-09-06 学校法人麻布獣医学園 てんかん発作のモニタリングシステム及びモニタリング方法
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
EP3150598B1 (en) 2014-05-28 2019-02-13 TOA Eiyo Ltd. Substituted tropane derivatives
CA2961410C (en) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
WO2016118391A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2017027651A1 (en) 2015-08-12 2017-02-16 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044021A (en) 1971-10-21 1977-08-23 American Cyanamid Company Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en) 1975-02-07 1976-01-13 Morton-Norwich Products, Inc. 1-Arylmethyl-2-imidazolidinones
DE19532668A1 (de) * 1995-09-05 1997-03-06 Dresden Arzneimittel Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
US5869481A (en) * 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19721580A1 (de) * 1997-05-23 1998-11-26 Dresden Arzneimittel Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
JP2002507211A (ja) * 1997-06-26 2002-03-05 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ジヒドロホノキオール組成物の合成
JP4669095B2 (ja) 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
EP1485094B2 (de) 2002-03-07 2020-03-25 Boehringer Ingelheim International GmbH Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
KR20140057604A (ko) 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals

Also Published As

Publication number Publication date
HUS1300035I1 (hu) 2017-10-30
HRP20090667A2 (hr) 2010-07-31
DK1553952T3 (da) 2009-04-20
JP2014080449A (ja) 2014-05-08
JP2011068685A (ja) 2011-04-07
US20130065898A1 (en) 2013-03-14
US8962617B2 (en) 2015-02-24
AU2003273978B2 (en) 2009-07-23
BE2013C046I2 (nl) 2022-08-09
EP2845594B1 (en) 2022-02-23
LU92238I2 (fr) 2013-09-03
EP1553952A1 (en) 2005-07-20
KR20050056237A (ko) 2005-06-14
NZ539864A (en) 2007-11-30
ES2908453T3 (es) 2022-04-29
WO2004032938A1 (en) 2004-04-22
FR22C1033I1 (fr) 2022-09-09
CY1109961T1 (el) 2014-09-10
US20150072983A1 (en) 2015-03-12
DK2845594T3 (da) 2022-03-07
PL214702B1 (pl) 2013-09-30
HRP20200207A2 (hr) 2020-07-24
BR0315225A (pt) 2005-08-23
US9469611B2 (en) 2016-10-18
CY1125103T1 (el) 2023-01-05
KR20110063843A (ko) 2011-06-14
ATE418337T1 (de) 2009-01-15
ES2316808T3 (es) 2009-04-16
ZA200502245B (en) 2005-11-30
CN1726040B (zh) 2010-05-12
SI1553952T1 (sl) 2009-04-30
CA2727722A1 (en) 2004-04-22
DE60325496D1 (de) 2009-02-05
US8859540B2 (en) 2014-10-14
FR13C0044I2 (fr) 2014-03-07
PL374603A1 (en) 2005-10-31
AU2003273978A1 (en) 2004-05-04
TWI424849B (zh) 2014-02-01
HRP20050322A2 (en) 2006-05-31
AU2009225322A1 (en) 2009-11-05
FR13C0044I1 (nl) 2013-08-30
US20080027057A1 (en) 2008-01-31
PT2845594T (pt) 2022-03-09
MXPA05003663A (es) 2005-06-08
CA2727722C (en) 2013-05-28
JP2006503873A (ja) 2006-02-02
US20160367562A1 (en) 2016-12-22
HRP20050322B1 (hr) 2013-12-06
CY2013031I1 (el) 2015-11-04
CN101890019A (zh) 2010-11-24
EP1553952B1 (en) 2008-12-24
CN1726040A (zh) 2006-01-25
CA2501772A1 (en) 2004-04-22
TWI324067B (en) 2010-05-01
AR041573A1 (es) 2005-05-18
JP2016104817A (ja) 2016-06-09
HRP20090667B1 (hr) 2021-06-11
CA2501772C (en) 2011-08-23
TW201010706A (en) 2010-03-16
HUS2200036I1 (hu) 2022-08-28
CY2013031I2 (el) 2015-11-04
EP2845594A1 (en) 2015-03-11
LU92238I9 (nl) 2019-01-09
PT1553952E (pt) 2009-02-10
EP2036563A1 (en) 2009-03-18
PL397320A1 (pl) 2012-02-13
SI2845594T1 (sl) 2022-04-29
PL238776B1 (pl) 2021-10-04
TW200503726A (en) 2005-02-01
KR101110587B1 (ko) 2012-02-15
JP4694202B2 (ja) 2011-06-08
US20050070537A1 (en) 2005-03-31
JP6249812B2 (ja) 2017-12-20

Similar Documents

Publication Publication Date Title
HK1085920A1 (en) Use of dihydroimidazolones for the manufacture of a medicament for the treatment of epilepsy in dogs
IL183506A (en) Use of a compound for the preparation of a drug for the treatment of diseases of breast tumors
GB0216321D0 (en) Therapeutic treatment
EP1469812A4 (en) ORAL INSULIN THERAPY
GB0316912D0 (en) Therapeutic treatment
GB0320806D0 (en) Therapeutic treatment
GB0201674D0 (en) Medical treatment
HK1078784A1 (en) Therapeutic treatment
GB0223367D0 (en) Therapeutic treatment
GB0218879D0 (en) Medical treatment
GB0219660D0 (en) Therapeutic use
GB0210464D0 (en) Therapeutic treatment
AU2003296545A8 (en) Use of a trpm8-activating substance for the treatment of tumours
GB0307863D0 (en) Therapeutic treatment
GB0313772D0 (en) Therapeutic treatment
GB0327493D0 (en) Treatment medicament
GB0203672D0 (en) A treatment
GB0211297D0 (en) Pain treatment
IL164388A0 (en) Use of ranolazine for the preparation of a medicament for the treatment of arrhymias
SI1553950T1 (sl) Terapevtsko zdravljenje
GB0214885D0 (en) Medicament
GB0211377D0 (en) Medicament
GB0220849D0 (en) Medical treatment
GB0224353D0 (en) Medical treatment
GB0227865D0 (en) Medical Treatment

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20231008